Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer

Norihiko Masuda, Osamu Ogawa, Meyeon Park, Alvin Y. Liu, Steven Goodison, Yunfeng Dai, Landon Kozai, Hideki Furuya, Yair Lotan, Charles J. Rosser, Takashi Kobayashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A 10-plex urine-based bladder cancer (BCa) diagnostic signature has the potential to non-invasively predict the presence of BCa in at-risk patients, as reported in various case-control studies. The present meta-analysis was performed to reevaluate and demonstrate the robustness and consistency of the diagnostic utility of the 10-plex urine-based diagnostic assay. We re-analyzed primary data collected in five previously published case-control studies on the 10-plex diagnostic assay. Studies reported the sensitivity and specificity of ten urinary protein biomarkers for the detection of BCa, including interleukin 8, matrix metalloproteinases 9 and 10, angiogenin, apolipoprotein E, syndecan 1, alpha-1 antitrypsin, plasminogen activator inhibitor-1, carbonic anhydrase 9, and vascular endothelial growth factor A. Data were extracted and reviewed independently by two investigators. Log odds ratios (ORs) were calculated to determine how strongly the 10-plex biomarker panel and individual biomarkers are associated with the presence of BCa. Data pooled from 1,173 patients were analyzed. The log OR for each biomarker was improved by 1.5 or greater with smaller 95% CI in our meta-analysis of the overall cohort compared with each analysis of an individual cohort. The combination of the ten biomarkers showed a higher log OR (log OR: 3.46, 95% CI: 2.60-4.31) than did any single biomarker irrespective of histological grade or disease stage of tumors. We concluded that the 10-plex BCaassociated diagnostic signature demonstrated a higher potential to identify BCa when compared to any single biomarker. Our results justify further advancement of the 10-plex protein-based diagnostic signature toward clinical application.

Original languageEnglish (US)
Pages (from-to)7101-7111
Number of pages11
JournalOncotarget
Volume9
Issue number6
DOIs
StatePublished - Jan 1 2018

Fingerprint

Urinary Bladder Neoplasms
Meta-Analysis
Biomarkers
Urine
Odds Ratio
Case-Control Studies
Matrix Metalloproteinase 10
Syndecan-1
alpha 1-Antitrypsin
Plasminogen Activator Inhibitor 1
Matrix Metalloproteinase 9
Interleukin-8
Vascular Endothelial Growth Factor A
Proteins
Cohort Studies
Research Personnel
Sensitivity and Specificity
Neoplasms

Keywords

  • Diagnosis
  • Meta-analysis
  • Urinary bladder
  • Urine biomarkers
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology

Cite this

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer. / Masuda, Norihiko; Ogawa, Osamu; Park, Meyeon; Liu, Alvin Y.; Goodison, Steven; Dai, Yunfeng; Kozai, Landon; Furuya, Hideki; Lotan, Yair; Rosser, Charles J.; Kobayashi, Takashi.

In: Oncotarget, Vol. 9, No. 6, 01.01.2018, p. 7101-7111.

Research output: Contribution to journalArticle

Masuda, N, Ogawa, O, Park, M, Liu, AY, Goodison, S, Dai, Y, Kozai, L, Furuya, H, Lotan, Y, Rosser, CJ & Kobayashi, T 2018, 'Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer', Oncotarget, vol. 9, no. 6, pp. 7101-7111. https://doi.org/10.18632/oncotarget.23872
Masuda, Norihiko ; Ogawa, Osamu ; Park, Meyeon ; Liu, Alvin Y. ; Goodison, Steven ; Dai, Yunfeng ; Kozai, Landon ; Furuya, Hideki ; Lotan, Yair ; Rosser, Charles J. ; Kobayashi, Takashi. / Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer. In: Oncotarget. 2018 ; Vol. 9, No. 6. pp. 7101-7111.
@article{948ed10153b74434aad52d6c51bbe8b2,
title = "Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer",
abstract = "A 10-plex urine-based bladder cancer (BCa) diagnostic signature has the potential to non-invasively predict the presence of BCa in at-risk patients, as reported in various case-control studies. The present meta-analysis was performed to reevaluate and demonstrate the robustness and consistency of the diagnostic utility of the 10-plex urine-based diagnostic assay. We re-analyzed primary data collected in five previously published case-control studies on the 10-plex diagnostic assay. Studies reported the sensitivity and specificity of ten urinary protein biomarkers for the detection of BCa, including interleukin 8, matrix metalloproteinases 9 and 10, angiogenin, apolipoprotein E, syndecan 1, alpha-1 antitrypsin, plasminogen activator inhibitor-1, carbonic anhydrase 9, and vascular endothelial growth factor A. Data were extracted and reviewed independently by two investigators. Log odds ratios (ORs) were calculated to determine how strongly the 10-plex biomarker panel and individual biomarkers are associated with the presence of BCa. Data pooled from 1,173 patients were analyzed. The log OR for each biomarker was improved by 1.5 or greater with smaller 95{\%} CI in our meta-analysis of the overall cohort compared with each analysis of an individual cohort. The combination of the ten biomarkers showed a higher log OR (log OR: 3.46, 95{\%} CI: 2.60-4.31) than did any single biomarker irrespective of histological grade or disease stage of tumors. We concluded that the 10-plex BCaassociated diagnostic signature demonstrated a higher potential to identify BCa when compared to any single biomarker. Our results justify further advancement of the 10-plex protein-based diagnostic signature toward clinical application.",
keywords = "Diagnosis, Meta-analysis, Urinary bladder, Urine biomarkers, Urothelial carcinoma",
author = "Norihiko Masuda and Osamu Ogawa and Meyeon Park and Liu, {Alvin Y.} and Steven Goodison and Yunfeng Dai and Landon Kozai and Hideki Furuya and Yair Lotan and Rosser, {Charles J.} and Takashi Kobayashi",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23872",
language = "English (US)",
volume = "9",
pages = "7101--7111",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "6",

}

TY - JOUR

T1 - Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer

AU - Masuda, Norihiko

AU - Ogawa, Osamu

AU - Park, Meyeon

AU - Liu, Alvin Y.

AU - Goodison, Steven

AU - Dai, Yunfeng

AU - Kozai, Landon

AU - Furuya, Hideki

AU - Lotan, Yair

AU - Rosser, Charles J.

AU - Kobayashi, Takashi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A 10-plex urine-based bladder cancer (BCa) diagnostic signature has the potential to non-invasively predict the presence of BCa in at-risk patients, as reported in various case-control studies. The present meta-analysis was performed to reevaluate and demonstrate the robustness and consistency of the diagnostic utility of the 10-plex urine-based diagnostic assay. We re-analyzed primary data collected in five previously published case-control studies on the 10-plex diagnostic assay. Studies reported the sensitivity and specificity of ten urinary protein biomarkers for the detection of BCa, including interleukin 8, matrix metalloproteinases 9 and 10, angiogenin, apolipoprotein E, syndecan 1, alpha-1 antitrypsin, plasminogen activator inhibitor-1, carbonic anhydrase 9, and vascular endothelial growth factor A. Data were extracted and reviewed independently by two investigators. Log odds ratios (ORs) were calculated to determine how strongly the 10-plex biomarker panel and individual biomarkers are associated with the presence of BCa. Data pooled from 1,173 patients were analyzed. The log OR for each biomarker was improved by 1.5 or greater with smaller 95% CI in our meta-analysis of the overall cohort compared with each analysis of an individual cohort. The combination of the ten biomarkers showed a higher log OR (log OR: 3.46, 95% CI: 2.60-4.31) than did any single biomarker irrespective of histological grade or disease stage of tumors. We concluded that the 10-plex BCaassociated diagnostic signature demonstrated a higher potential to identify BCa when compared to any single biomarker. Our results justify further advancement of the 10-plex protein-based diagnostic signature toward clinical application.

AB - A 10-plex urine-based bladder cancer (BCa) diagnostic signature has the potential to non-invasively predict the presence of BCa in at-risk patients, as reported in various case-control studies. The present meta-analysis was performed to reevaluate and demonstrate the robustness and consistency of the diagnostic utility of the 10-plex urine-based diagnostic assay. We re-analyzed primary data collected in five previously published case-control studies on the 10-plex diagnostic assay. Studies reported the sensitivity and specificity of ten urinary protein biomarkers for the detection of BCa, including interleukin 8, matrix metalloproteinases 9 and 10, angiogenin, apolipoprotein E, syndecan 1, alpha-1 antitrypsin, plasminogen activator inhibitor-1, carbonic anhydrase 9, and vascular endothelial growth factor A. Data were extracted and reviewed independently by two investigators. Log odds ratios (ORs) were calculated to determine how strongly the 10-plex biomarker panel and individual biomarkers are associated with the presence of BCa. Data pooled from 1,173 patients were analyzed. The log OR for each biomarker was improved by 1.5 or greater with smaller 95% CI in our meta-analysis of the overall cohort compared with each analysis of an individual cohort. The combination of the ten biomarkers showed a higher log OR (log OR: 3.46, 95% CI: 2.60-4.31) than did any single biomarker irrespective of histological grade or disease stage of tumors. We concluded that the 10-plex BCaassociated diagnostic signature demonstrated a higher potential to identify BCa when compared to any single biomarker. Our results justify further advancement of the 10-plex protein-based diagnostic signature toward clinical application.

KW - Diagnosis

KW - Meta-analysis

KW - Urinary bladder

KW - Urine biomarkers

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85040902730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040902730&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23872

DO - 10.18632/oncotarget.23872

M3 - Article

AN - SCOPUS:85040902730

VL - 9

SP - 7101

EP - 7111

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 6

ER -